Pharmaceutical Business review

Evotec completes acquisition of Renovis

In exchange for each outstanding share of Renovis common stock, Renovis stockholders receive 0.5271 American depositary shares (ADSs) of Evotec.

Each Evotec ADS represents two ordinary shares of Evotec. As a result, Evotec is issuing an aggregate of 34.98 million new ordinary shares, which underly the ADSs issued to Renovis stockholders. Current Evotec stockholders now own approximately 68.8% of the combined company and Renovis stockholders own up to 31.2%.